RDY$14.4
$14.5836
Chart
Performance
Key Stats
AI RDY Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyDr. Reddy's Laboratories presents a mixed but generally positive investment profile. Strong profitability and consistent dividend payments are offset by recent underperformance and technical indicators suggesting caution. The company operates in a defensive sector with steady demand, making it a potentially stable addition to a diversified portfolio.
Thematic
Dr. Reddy's Laboratories operates within the global pharmaceutical industry, which benefits from long-term demographic trends such as an aging population and increasing healthcare spending. The company's focus on generics and active pharmaceutical ingredients (APIs) positions it well to benefit from cost-conscious healthcare systems and the growing demand for affordable medicines.
Fundamental
Dr. Reddy's Laboratories demonstrates robust financial health with strong profitability margins, consistent revenue generation, and a healthy balance sheet. The company's ability to consistently beat earnings estimates and maintain a reasonable valuation makes it an attractive fundamental investment.
Technical
The stock's technical indicators present a mixed picture. While it has experienced some recent positive performance (5D and 6M), the 1M and YTD performance shows a downward trend. Key technical oscillators and moving averages generally lean towards a 'Sell' or 'Neutral' signal, suggesting potential headwinds or consolidation in the short to medium term.
| Factor | Score |
|---|---|
| Aging Global Population | 80 |
| Healthcare Spending Growth | 85 |
| Generic Drug Market Expansion | 75 |
| API Manufacturing & Supply Chain | 70 |
| Biologics and Biosimilars | 60 |
| Factor | Score |
|---|---|
| Valuation | 80 |
| Profitability | 85 |
| Growth | 85 |
| Balance Sheet Health | 90 |
| Cash Flow | 85 |
| Dividend Yield | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 70 |
| Short-term Performance | 75 |
| Mid-term Performance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Positive Price Movement & Valuation
Current price of $14.71 shows a slight increase of 0.75%. The P/E TTM of 18.62 is within a reasonable range for the pharmaceutical sector, and the dividend yield of 0.5479452% offers some return to shareholders.
Recent Positive Performance
The stock has shown positive performance over the last 6 months (+7.77%) and in the short term (5 days: +1.1%). This indicates recent positive momentum.
Bearish Points (6)
Recent Price Decline
The stock price has experienced a negative performance over the last 1 month (-4.04%) and year-to-date (-6.13%), and a significant decline over the last year (-8.91%).
High Valuation in Certain Metrics
While the P/E TTM is 18.62, the valuation summary shows a P/E of 0.2 for 2025Q1 and 2024Q1, which seems anomalously low and might be due to large non-recurring items affecting net income. The P/S ratio in the valuation summary is consistently 0.0, which is not indicative of current valuation and suggests potential data issues or a specific reporting convention.
Calendar
August 2024
12
Next Dividend Date
July 2025
23
Next Earnings Date
H: $
A: $
L: $
H: 90.33B
A: 88.11B
L: 86.32B
July 2025
25
Ex-Dividend Date
Profile
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Seasonals
Price Target
15.19 USD
The 39 analysts offering 1 year price forecasts for RDY have a max estimate of 18.77 and a min estimate of 11.75.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Major Indian pharmaceutical company, a direct competitor to Dr. Reddy's in various generic and specialty segments, strong presence in key markets.
Weight: 97
Leading Indian pharmaceutical company with a significant global presence, directly competes with Dr. Reddy's across several therapeutic areas including generics.
Weight: 96
Prominent Indian pharmaceutical company known for its generics, respiratory, and anti-infective products, a direct competitor in India and other emerging markets.
Weight: 95
Large Indian generics manufacturer, strong in APIs and finished dosages, directly competes with Dr. Reddy's in the generic pharmaceutical space.